



## BioPharmica Limited

November 1<sup>st</sup>, 2006  
BioPharmica (ASX: BPH) ASX Release

### **BIOPHARMICA AND GE HEALTHCARE COLLABORATION UPDATE**

Molecular Discovery Systems (MDS), a wholly owned subsidiary of ASX-listed Perth biotech company BioPharmica Ltd (ASX: BPH), has entered into a number of separate agreements with one of the world's largest healthcare companies, GE Healthcare.

The relationship consists of **three** separate agreements:

#### **[1] Collaborative Research Agreement**

The collaboration will see MDS researchers work with GE Healthcare teams in the US, UK, Australia and Singapore. The work will focus on the application and extension of cell-based imaging technology. Within this agreement there are two separate areas of focus:

- A) The imaging and analysis of cancer patient tissue samples.
- B) The use and development of imaging assays in signaling pathways. A key research milestone will centre around investigating HLS5, a gene now being commercialised by BioPharmica.

#### **[2] Consultancy Services Agreement**

MDS, from its Perth head office, will provide consultancy services to GE Healthcare and its customers in the Asian region.

#### **[3] A Show Site Agreement**

This will recognise the WAIMR (Western Australian Institute for Medical Research) labs of MDS as a specialty imaging site and key location to showcase current and future GE Healthcare imaging technologies to partners and customers in the Asian region.

Commenting on the relationship, Stephen McIntyre, President, GE Healthcare, Australia/New Zealand said, "GE Healthcare has always placed value on developing partnerships and working with customers to achieve common objectives.

"Co-operative efforts like this one see our vast experience come into play, and ensure our advanced technology is used to support innovative, groundbreaking and necessary research projects."

BioPharmica Director Charles Murphy agreed the GE collaboration would support mutual goals.

"In some areas of the collaboration one party will own intellectual property and in other areas MDS and GE Healthcare will share it," explained Mr Murphy. "Both MDS and GE Healthcare are seeking to increase the impact of cell-based imaging on research and patient care."

"MDS will play a vital role in BioPharmica's investment portfolio, enhancing the capacity to invest into and commercialise world-leading Australian science."



## **BioPharmica Limited**

### **About GE Healthcare**

GE Healthcare is a \$15 billion unit of GE that provides transformational medical technologies that are shaping a new age of patient care. GE Healthcare's expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, disease research, drug discovery and biopharmaceuticals is dedicated to detecting disease earlier and tailoring treatment for individual patients. GE Healthcare offers a broad range of services to improve productivity in healthcare and enable healthcare providers to better diagnose, treat and manage patients with conditions such as cancer, Alzheimer's and cardiovascular diseases.

### **About Molecular Discovery Systems**

Molecular Discovery Systems is a subsidiary of ASX listed BioPharmica Ltd (ASX: BPH) and has core expertise in verification and validation of both assays and analysis. The company focuses on drug discovery with the validation of biomarkers for disease, therapy and diagnostics. The approach taken is to provide a structured approach to the validation process of biomarker discovery at the earliest stages.

### **About BioPharmica**

BioPharmica (ASX: BPH) is an Australian Stock Exchange listed company developing biomedical research with academic and hospital institutes. The Company provides early stage funding for a direct collaboration, a spin out company or to secure a license. BioPharmica provides product development, funding and commercial strategies, whilst the institutional partner provides a majority of the infrastructure and research expertise.

**MORE INFORMATION: Charles Murphy, Director, Tel (08) 9328 8366.**

Yours Faithfully,

David Breeze  
Chairman

#### **BioPharmica Limited**

ACN 95 912 002

PO Box 317, North Perth 6906, Western Australia  
14 View Street, North Perth, Western Australia 6006  
admin@biopharmica.com.au www.biopharmica.com.au  
T: +61 8 9328 8366 F: +61 8 9328 8733